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In this issue of Cell Reports, Emmanuel et al. (2017) report that mTORC1 activity is regulated by pu-
rine availability. This increases the number of mTORC1 regulators to include metabolites whose
synthesis mTORC1 controls.mTORC1 is a major signaling hub that
integrates inputs from varying nutrient,
energy, and growth factor levels to regu-
late cell growth. Broadly, mTORC1 acti-
vates anabolic processes required for
cell growth, including protein, nucleotide,
and lipid synthesis. Conversely, mTORC1
inactivity lifts restraints on catabolic pro-
cesses, such as autophagy, that enable
the cell to sustain itself when resources
are scarce.
Given the central role of mTORC1 activ-
ity in growth and metabolism, it is not
surprising that it is tightly regulated. Stim-
uli are funneled into mTORC1 via the
GTPase Rheb, the immediate upstream
activator of mTORC1. Only GTP-bound
Rheb activates mTORC1, and it is modu-
lation of the Rheb GTP/GDP-loading sta-
tus that ultimately determines mTORC1
activity.
Nucleotide biosynthesis (both pyrimi-
dine and purine) is among the anabolic
pathways activated by mTORC1 (Robi-
taille et al., 2013; Ben-Sahra et al., 2013;
2016). Besides its well-known role as a
DNA building block, GTP also mediates
protein synthesis and cytoskeletal dy-
namics and is a second messenger in
signaling cascades. Depletion of the
intra-cellular pool of GTP has an anti-pro-
liferative effect andmay be an anti-cancer
strategy.
In this issue of Cell Reports, Emmanuel
et al. report that GTP availability can con-
trol mTORC1 activity by determining the
GTP-loading status of Rheb. Pharmaco-
logical inhibition of purine biosynthesis
had an inhibitory effect onmTORC1, while
inhibition of pyrimidine biosynthesis had
no impact on mTORC1 activity. mTORC1
inhibition upon GTP depletion coincided
with reduced proliferation. Exogenous
adenine or guanine suppressed the effect
of de novo purine biosynthesis inhibitionThis is an open access aron mTORC1 activity. However, only gua-
nine could rescue mTORC1 activity upon
inhibition of IMPDH1/2 (the guanine-
specific step after the branchpoint for
adenine and guanine synthesis), suggest-
ing that it is guanine availability that is
responsible for the observed effects on
mTORC1 activity.
The authors found that GTP depletion
reduced GTP loading of Rheb without
affecting the activity or GTP loading of
other GTPases such as Ras and Rac1
(and presumably Rag, see below), indi-
cating that Rheb is particularly responsive
to intra-cellular GTP concentration.
mTORC1 activity is also regulated by
another set of G proteins, the Rags, that
activate mTORC1 in response to amino
acids. Ectopic expression of a constitu-
tively active form of the RagB/C hetero-
dimer (which corresponds to RagBGTP/
RagCGDP) rendered mTORC1 resistant
to amino acid deprivation but was unable
to prevent mTORC1 inhibition by purine
synthesis inhibitors. However, constitu-
tively active Rheb was able to rescue
mTORC1 activity upon purine depletion,
suggesting that the effect of GTP deple-
tion on mTORC1 activation is primarily
or solely via Rheb.
These results add a new dimension to
the relationship between mTORC1 and
purine synthesis, in particular for GTP. It
places GTP both upstream and down-
stream of mTORC1. In proliferating cells,
mTORC1 stimulates de novo purine
biosynthesis, and adequate intra-cellular
GTP levels are required to sustain
mTORC1 activity. What is the physiolog-
ical significance of this new relationship?
It may simply be a positive feedback
mechanism to amplify mTORC1 activity.
Conversely, could the purpose be that
low GTP levels play a role in inhibiting
mTORC1 signaling, and if so, under whatCell Reports 19,
ticle under the CC BY-NC-ND license (http://crconditions would mTORC1 be negatively
regulated by lowGTP levels? A physiolog-
ical situation in which GTP levels are
insufficient to activate mTORC1 would
presumably arise only after prolonged pe-
riods of nutrient unavailability (and thus
reducedmTORC1-mediated GTP synthe-
sis) when mTORC1 is already inactive.
Indeed, Emmanuel et al. studied the effect
of GTP depletion after extended inhibition
of purine synthesis (overnight to 24 hr).
mTORC1 typically responds to positive
signals within seconds to minutes, thus
allowing cells to mount a real-time
response to fluctuating extra- and intra-
cellular conditions. For example, rapid
mTORC1 activation upon sudden avail-
ability of nutrients (following feeding or
acquisition of a food source) calls for
quick mobilization of metabolic pathways
to assimilate the newly available re-
sources. In contrast, turning off mTORC1
(such as upon limiting GTP or nutrient
levels) would occur only after resource
exhaustion and dissipation of an acti-
vating signal. This could be accomplished
by dissociation of activating complexes
or, as seen in the present case, limitation
of GTP required for Rheb-dependent
mTORC1 activation. Thus, there may be
negative regulation of mTORC1 that oper-
ates over a gradual timescale (by compar-
ison with rapid activation).
A key finding of this study is that a
metabolite whose synthesis depends on
mTORC1 is able to regulate mTORC1.
This is similar to the case of the
metabolic intermediate a-ketoglutarate.
mTORC1 stimulates glutaminolysis and
glutamine anaplerosis of the tricarboxylic
acid cycle (Csibi, et al., 2013). This is
achieved by increasing the activity of
the glutaminolytic enzyme glutamate
dehydrogenase (GDH) via mTORC1-
mediated transcriptional repression ofJune 27, 2017 ª 2017 The Author(s). 2643
eativecommons.org/licenses/by-nc-nd/4.0/).
its upstream inhibitor SIRT4. GDH pro-
duces a-ketoglutarate, which in turn acti-
vates mTORC1 by promoting mTORC1
translocation to the lysosome (Dura´n,
et al., 2012). Is mTORC1 regulation by
downstream products a general phe-
nomenon? Future studies will establish
if it is indeed a common feature of
mTORC1 signaling and its physiological
implications.2644 Cell Reports 19, June 27, 2017REFERENCES
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